{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:21:02Z","timestamp":1783948862060,"version":"3.55.0"},"reference-count":68,"publisher":"Elsevier","isbn-type":[{"value":"9780128186770","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.mie.2019.05.043","type":"book-chapter","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T11:13:54Z","timestamp":1561461234000},"page":"205-230","source":"Crossref","is-referenced-by-count":11,"title":["Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition"],"prefix":"10.1016","member":"78","reference":[{"issue":"6","key":"10.1016\/bs.mie.2019.05.043_bb0010","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","article-title":"IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients","volume":"107","author":"Ahmadzadeh","year":"2006","journal-title":"Blood"},{"issue":"15","key":"10.1016\/bs.mie.2019.05.043_bb0015","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.mie.2019.05.043_bb0020","first-page":"36","article-title":"Oncolytic adenoviruses in cancer treatment","volume":"2","author":"Alemany","year":"2014","journal-title":"Biomedicine"},{"issue":"15","key":"10.1016\/bs.mie.2019.05.043_bb0025","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"12","key":"10.1016\/bs.mie.2019.05.043_bb0030","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1080\/21645515.2015.1075106","article-title":"Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma","volume":"11","author":"Andersen","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"5","key":"10.1016\/bs.mie.2019.05.043_bb0035","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/bs.mie.2019.05.043_bb0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"issue":"26","key":"10.1016\/bs.mie.2019.05.043_bb0045","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mie.2019.05.043_bb0050","series-title":"Advances in cancer research","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-12-398342-8.00008-2","article-title":"Chapter eight\u2014Oncolytic adenoviruses for cancer immunotherapy: Data from mice, hamsters, and humans","volume":"115","author":"Cerullo","year":"2012"},{"issue":"11","key":"10.1016\/bs.mie.2019.05.043_bb0055","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/bs.mie.2019.05.043_bb0060","series-title":"AACR tumor immunology and immunotherapy meeting","article-title":"Enabling checkpoint inhibitors with oncolytic viruses to deliver complete responses: A matter of timing","author":"Cervera-Carrascon","year":"2018"},{"issue":"5","key":"10.1016\/bs.mie.2019.05.043_bb0065","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1412902","article-title":"TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.mie.2019.05.043_bb0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/bs.mie.2019.05.043_bb0075","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.mie.2019.05.043_bb0080","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Therapy"},{"issue":"10","key":"10.1016\/bs.mie.2019.05.043_bb0085","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00262-015-1735-z","article-title":"Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma","volume":"64","author":"Guislain","year":"2015","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/bs.mie.2019.05.043_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omto.2018.10.005","article-title":"Abscopal effect in non-injected tumors achieved with cytokine-armed oncolytic adenovirus","volume":"11","author":"Havunen","year":"2018","journal-title":"Molecular Therapy Oncolytics"},{"key":"10.1016\/bs.mie.2019.05.043_bb0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Molecular Therapy Oncolytics"},{"issue":"9","key":"10.1016\/bs.mie.2019.05.043_bb0100","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"8","key":"10.1016\/bs.mie.2019.05.043_bb0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"14","key":"10.1016\/bs.mie.2019.05.043_bb0110","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Research"},{"issue":"10","key":"10.1016\/bs.mie.2019.05.043_bb0115","first-page":"2268","article-title":"Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal","volume":"21","author":"Kageyama","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/bs.mie.2019.05.043_bb0120","first-page":"275","article-title":"Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells","volume":"8","author":"Kanerva","year":"2002","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1016\/bs.mie.2019.05.043_bb0125","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.mie.2019.05.043_bb0130","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nature Reviews Drug Discovery"},{"issue":"16","key":"10.1016\/bs.mie.2019.05.043_bb0135","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1089\/10430340260355374","article-title":"Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2","volume":"13","author":"Kershaw","year":"2002","journal-title":"Human Gene Therapy"},{"issue":"7","key":"10.1016\/bs.mie.2019.05.043_bb0140","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-015-1691-7","article-title":"Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-gamma) in metastatic melanoma patients","volume":"64","author":"Khammari","year":"2015","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"2","key":"10.1016\/bs.mie.2019.05.043_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: How lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends in Immunology"},{"issue":"14","key":"10.1016\/bs.mie.2019.05.043_bb0150","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: Replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"5256","key":"10.1016\/bs.mie.2019.05.043_bb0155","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"7","key":"10.1016\/bs.mie.2019.05.043_bb0160","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.it.2018.04.005","article-title":"Update on tumor neoantigens and their utility: Why it is good to be different","volume":"39","author":"Lee","year":"2018","journal-title":"Trends in Immunology"},{"issue":"2","key":"10.1016\/bs.mie.2019.05.043_bb0165","doi-asserted-by":"crossref","DOI":"10.4161\/23723556.2014.976507","article-title":"Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"4","author":"Li","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/bs.mie.2019.05.043_bb0170","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/gt.2008.179","article-title":"A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients","volume":"16","author":"Li","year":"2008","journal-title":"Gene Therapy"},{"issue":"23","key":"10.1016\/bs.mie.2019.05.043_bb0175","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"issue":"29","key":"10.1016\/bs.mie.2019.05.043_bb0180","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","article-title":"Treatment of patients with metastatic cancer using a major histocompatibility complex class II\u2013restricted T-cell receptor targeting the cancer germline antigen MAGE-A3","volume":"35","author":"Lu","year":"2017","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.mie.2019.05.043_bb0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"3","key":"10.1016\/bs.mie.2019.05.043_bb0190","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2018.107","article-title":"A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients","volume":"30","author":"Margarita","year":"2019","journal-title":"Human Gene Therapy"},{"issue":"5","key":"10.1016\/bs.mie.2019.05.043_bb0195","first-page":"439","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic","volume":"378","author":"Maude","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.mie.2019.05.043_bb0200","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.trecan.2015.07.008","article-title":"Immune response to cancer therapy: Mounting an effective antitumor response and mechanisms of resistance","volume":"1","author":"Medler","year":"2015","journal-title":"Trends in Cancer"},{"issue":"2","key":"10.1016\/bs.mie.2019.05.043_bb0205","first-page":"133","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"Journal of Immunotherapy (Hagerstown, Md: 1997)"},{"issue":"2","key":"10.1016\/bs.mie.2019.05.043_bb0210","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/mt.2009.262","article-title":"A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors","volume":"18","author":"Nemunaitis","year":"2010","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"18","key":"10.1016\/bs.mie.2019.05.043_bb0215","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor\u2013modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Research"},{"issue":"10","key":"10.1016\/bs.mie.2019.05.043_bb0220","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non\u2013muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"7","key":"10.1016\/bs.mie.2019.05.043_bb0225","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: Assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Research"},{"key":"10.1016\/bs.mie.2019.05.043_bb0230","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/gt.2010.17","article-title":"Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5\/3-Cox2L-D24 in patients with metastatic and refractory solid tumors","volume":"17","author":"Pesonen","year":"2010","journal-title":"Gene Therapy"},{"key":"10.1016\/bs.mie.2019.05.043_bb0235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors\u2014An evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"6","key":"10.1016\/bs.mie.2019.05.043_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"6382","key":"10.1016\/bs.mie.2019.05.043_bb0245","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"6230","key":"10.1016\/bs.mie.2019.05.043_bb0250","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science (New York, N.Y.)"},{"issue":"13","key":"10.1016\/bs.mie.2019.05.043_bb0255","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1016\/bs.mie.2019.05.043_bb0260","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"7","key":"10.1016\/bs.mie.2019.05.043_bb0265","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nature Biotechnology"},{"issue":"4","key":"10.1016\/bs.mie.2019.05.043_bb0270","first-page":"215","article-title":"Host tissue determinants of tumour immunity","volume":"19","author":"Salmon","year":"2019","journal-title":"Nature Reviews Cancer"},{"issue":"9","key":"10.1016\/bs.mie.2019.05.043_bb0275","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ymthe.2018.06.001","article-title":"Adenovirus coding for interleukin-2 and tumor necrosis factor alpha replaces lymphodepleting chemotherapy in adoptive T cell therapy","volume":"26","author":"Santos","year":"2018","journal-title":"Molecular Therapy"},{"issue":"7","key":"10.1016\/bs.mie.2019.05.043_bb0280","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ijc.30839","article-title":"Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy","volume":"141","author":"Santos","year":"2017","journal-title":"International Journal of Cancer"},{"issue":"17","key":"10.1016\/bs.mie.2019.05.043_bb0285","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"8","key":"10.1016\/bs.mie.2019.05.043_bb0290","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/mt.2016.137","article-title":"Adenoviral delivery of tumor necrosis factor-alpha and interleukin-2 enables successful adoptive cell therapy of immunosuppressive melanoma","volume":"24","author":"Siurala","year":"2016","journal-title":"Molecular Therapy"},{"issue":"8","key":"10.1016\/bs.mie.2019.05.043_bb0295","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2326-6066.CIR-14-0220-T","article-title":"Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor","volume":"3","author":"Tahtinen","year":"2015","journal-title":"Cancer Immunology Research"},{"issue":"6","key":"10.1016\/bs.mie.2019.05.043_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131242","article-title":"Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors","volume":"10","author":"Tahtinen","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/bs.mie.2019.05.043_bb0305","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-16-1577","article-title":"Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors","volume":"77","author":"Tanoue","year":"2017","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/bs.mie.2019.05.043_bb0310","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annual Review of Immunology"},{"issue":"1","key":"10.1016\/bs.mie.2019.05.043_bb0315","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nature Communications"},{"issue":"7","key":"10.1016\/bs.mie.2019.05.043_bb0320","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/bs.mie.2019.05.043_bb0325","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CAR-T cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunology Research"},{"issue":"14","key":"10.1016\/bs.mie.2019.05.043_bb0330","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/bs.mie.2019.05.043_bb0335","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses","volume":"23","author":"Woller","year":"2015","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.mie.2019.05.043_bb0340","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: Have we found the key to unleash the antitumor immune response?","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"10.1016\/bs.mie.2019.05.043_bb0345","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"The New England Journal of Medicine"}],"container-title":["Methods in Enzymology","Tumor Immunology and Immunotherapy \u2013 Integrated Methods Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0076687919302137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0076687919302137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:26:29Z","timestamp":1758749189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0076687919302137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128186770"],"references-count":68,"URL":"https:\/\/doi.org\/10.1016\/bs.mie.2019.05.043","relation":{},"ISSN":["0076-6879"],"issn-type":[{"value":"0076-6879","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}